Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Heck, MM; Koll, FJ; Retz, M; Autenrieth, M; Magg, K; Lunger, L; Gschwend, JE; Nawroth, R.
Molecular lymph node staging for bladder cancer patients undergoing radical cystectomy with pelvic lymph node dissection.
Urol Oncol. 2020; 38(7): 639.e11-639.e19.
Doi: 10.1016/j.urolonc.2020.01.018
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Koll Florestan Johannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: Presence of lymph node (LN) metastasis in bladder cancer (BCa) is a main risk factor for tumor recurrence after radical cystectomy (RC). Molecular analysis facilitates detection of small-volume LN metastases with higher sensitivity than standard histopathology. The aim of the present study was to establish molecular LN analysis in BCa patients undergoing RC with lymph node dissection (LND) and to determine its ability to predict tumor recurrence. PATIENTS AND METHODS: Five transcripts with overexpression in BCa (FXYD3, KRT17, KRT20, SPINK1, UPKII) were evaluated for molecular LN analysis. We included 76 BCa patients from the prospective, randomized surgical phase-III trial (LEA AUO AB 25/02, NCT01215071) investigating extended vs. limited LND at RC. The primary endpoint was recurrence-free survival (RFS). As control, 136 LNs from 45 patients without BCa were analyzed to determine a threshold for pathologic gene expression. RESULTS: About 1,319 LNs were investigated with molecular and histopathologic examination. Histopathology detected 39 LN metastases in 17 (22%) patients. Of the tested genes FXYD3 performed best and classified all pN+-patients correctly as node-positive (pN+/molN+). In addition, FXYD3 reclassified 43 histopathologic negative LNs and 7 (9%) pN0-patients as molecular node-positive (pN0/molN+). Molecular and histopathologic LN status (pN0/molN0 vs. pN0/molN+ vs. pN+/molN+) was significantly associated with locally advanced disease (P = 0.006) and poor RFS (P < 0.001). Median RFS was not reached in LN-negative patients (pN0/molN0), 45 months (95%CI 8-83) in exclusively molecular positive patients (pN0/molN+) and 9 months (95%CI 5-13) in patients with histopathologic and molecular positive LNs (pN+/molN+). CONCLUSIONS: Molecular LN analysis with FXYD3 identified additional LN metastases in histopathologic negative LNs and identified patients with elevated risk of tumor recurrence after RC. Thus, molecular LN analysis improves LN staging and might serve as a tool to guide adjuvant treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Cystectomy - methods
- Female - administration & dosage
- Humans - administration & dosage
- Lymph Node Excision - methods
- Lymph Nodes - pathology
- Male - administration & dosage
- Middle Aged - administration & dosage
- Urinary Bladder Neoplasms - complications, pathology, surgery
- Find related publications in this database (Keywords)
- Bladder cancer
- Biomarker
- Molecular marker
- Lymph node metastasis
- Lymph node dissection